Abbott has a diversified business, exciting growth avenues, and a strong dividend program. The company faces potential obstacles, including legal problems and stiff competition. However, that's no ...

Since my previous article, shares of Abbott Laboratories have returned 10 ... It's just not up to par with what I would need to see to maintain my buy rating. I would need to see a pullback to ...

Analyst Larry Biegelsen from Wells Fargo maintained a Buy rating on Abbott Laboratories (ABT – Research Report) and keeping the price target at $133.00. Larry Biegelsen has given his Buy rating ...

Abbott Laboratories (ABT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst ...

The CEO at the Illinois-based company with operations in Minnesota expects earning to return to a pre-pandemic profit model ...

The ABBOTT PRISM system is intended for in vitro diagnostic use only. A high throughput, highly automated test system for blood screening: The ABBOTT PRISM is a fully automated, high-volume blood ...

Newsweek magazine delivered to your door Newsweek Voices: Diverse audio opinions Enjoy ad-free browsing on Newsweek.com Comment on articles Newsweek app updates on-the-go ...

If a company's history and track record were good enough reasons to buy its shares, it'd be easy to make a case for investing in Abbott Laboratories (NYSE: ABT). Abbott is a longtime leader in the ...